Actively Recruiting
Phase 4 Pilot Study of Acthar Gel Injected Twice Weekly Using SelfJect Injector for Moderate to Severe Keratitis and Autoimmune Disease Effects on Corneal Nerves and Neuropathic Eye Pain
Led by Toyos Clinic · Updated on 2025-05-11
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of Acthar Gel injected subcutaneously via a single-dose pre-filled SelfJect injector in patients with moderate to severe keratitis related to systemic autoimmune diseases and associated dry eye. This open-label pilot study involves 20 autoimmune patients who have demonstrated a peripheral corneal pain component through the proparacaine challenge. The study aims to assess improvements in symptoms related to ocular pain, corneal nerve appearance and function, and common neuropathic pain symptoms caused by dysfunctional nerves due to autoimmune inflammatory disease. Participants will receive 80 units of Acthar Gel twice weekly using the SelfJect injector for 12 weeks. This treatment is intended to improve the subjective sensation of ocular pain, conjunctival and corneal staining, and corneal nerve health as visualized by confocal microscopy and Cochet-Bonnet esthesiometry. The study includes one active treatment arm where at least 16 patients will complete the 12-week dosing period. Patients will be followed for up to 3 years after treatment to monitor changes in visual acuity, corneal and conjunctival staining, and neuropathic pain symptoms. During the study, participants will be assessed using various visual analog scales VAS for injection comfort, burning, stinging, and light sensitivity over the 3-year follow-up period. Confocal imaging will be used to evaluate corneal nerves, and patient-reported outcomes will track neuropathic pain symptoms and comfort with the SelfJect injector. Safety and symptom improvements will be monitored regularly, with continued observation for long-term changes after the treatment period ends.
CONDITIONS
Brief Title
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
Research Team
H
Harley cheney Study Coordinator, Study Coordinator
M
Melissa Toyos, MD, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here